Cantor Fitzgerald reiterates Overweight on PTC Therapeutics, $137 target
Cantor Fitzgerald maintained an Overweight rating on PTC Therapeutics and kept a $137.00 price target, implying 109.9% upside from the Sep 21 close of $65.26.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.